REG - OptiBiotix Health - Launch of LeanBiome with global nutrition leader

OptiBiotix HealthAnnouncement

01/12/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211201:nRSA1039Ua&default-theme=true

RNS Number : 1039U  OptiBiotix Health PLC  01 December 2021

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Launch of LeanBiome(TM) with global leader in beauty & nutrition brands

 

OptiBiotix Health plc (AIM: OPTI), announces the launch of a new sports
nutrition product range branded LeanBiome(TM) alongside a new supply &
licensing agreement with a leading global player in beauty & nutrition
("the Partner"). This agreement grants the Partner a license to manufacture
and sell finished products containing LeanBiome(TM) across Europe, Australia
and Asia.

 

OptiBiotix is a life sciences business developing patented science and human
study-based compounds that modulate the microbiome to address metabolic
syndrome and diabetes, systemic low-grade inflammation, obesity,
cardiovascular disease, high cholesterol and supports healthy aging.

 

The Partner is a British e-commerce company which specialises in taking
beauty and nutrition brands direct to consumer ("D2C") through its proprietary
e-commerce platform across the globe. The Partner's technology, brand building
expertise, and global infrastructure allows it to reach millions of customers
around the world. They own the largest D2C sports nutrition brand globally.

 

LeanBiome(TM) is a scientifically formulated sports nutrition ingredient
which has been developed by OptiBiotix that supports athletes seeking to
increase lean muscle mass to change their body composition.
LeanBiome(TM) contains a patented combination of fibres, prebiotics and
minerals aimed specifically at supporting the microbiome diversity of athletes
on a high protein diet. LeanBiome(TM) adds unique differentiation to a new
premium product line of the Partner and will get on-pack recognition. The new
product line of the Partner is aimed at increasing lean muscle mass which is
scheduled to be rolled out from January 2022 in Europe and Asia. If the
product line is successful, it is expected to be introduced to the North
American market in due course. The agreement is expected to generate
approximately £1m in annualised and recurring turnover for the Company
starting in 2022. First orders worth £200k have been placed and are on
schedule for delivery in early December 2021.

 

There is growing scientific evidence of an anecdotal link between the
microbiome and athletic performance (Do microbes affect athletic performance?
(nature.com) (https://www.nature.com/articles/d41586-021-00821-6) .

 

This agreement is part of OptiBiotix's strategy to offer pro- and prebiotic
solutions aimed at modulating the microbiome that allow leading brands to
differentiate their health & wellness products.

 

René Kamminga, CEO of OptiBiotix Limited, commented: "We are very pleased
to announce this agreement with the Partner and its sports nutrition division.
LeanBiome(TM) has been specifically formulated with the needs of athletes in
mind and builds on our core expertise in functional ingredients with effect on
the microbiome to achieve health effects. The Partner is a formidable company
to partner with and we are pleased that LeanBiomeª has been selected as the
preferred source of differentiation for their new product line. This launch is
another important step in building sales and brand presence for
OptiBiotix' solutions with major partners around the world."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

 

For further information, please contact:

 

 OptiBiotix Health plc                                     www.optibiotix.com (http://www.optibiotix.com/)
 Stephen O'Hara, Chief Executive  Contact via Walbrook below

 Cairn Financial Advisers LLP (NOMAD)                      Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Cenkos Securities plc (Broker)                            Tel: 020 7397 8900
 Callum Davidson / Neil McDonald
 Michael Johnson / Russell Kerr (Sales)

 Walbrook PR Ltd                                           Mob: 07876 741 001
 Anna Dunphy

 

 

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identiÞed by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions. These forward looking statements are not
based on historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements reßect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRDBLFXFFLLFBZ